|This Slide: #46 of 100|
Slide #46. Forest Laboratories — Aptalis
Forest Laboratories (FRX)
Forest Laboratories, Inc. announced that it has entered into a definitive agreement to acquire Aptalis, a privately held U.S. based specialty Gastrointestinal (GI) and Cystic Fibrosis company, for $2.9 billion in cash from its shareholders, including TPG, the global private investment firm. The acquisition, which requires review by anti-trust authorities in the US and Canada, is expected to be accretive to Forest's FY2015 non-GAAP EPS.
Forest Road is a blank check company whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
Open the FRX Page at The Online Investor »
Free FRX Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Hold (2.47 out of 4)
(ranked higher than approx. 54% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite